Abstract
The pharmacological treatment of insomnia, epilepsy and panic disorders today includes the use of classical benzodiazepines and nonbenzodiazepines. However, therapy is accompanied by well-known side-effects resulting from insufficient target selectivity for different GABAA receptor subtypes. Highly selective GABAA receptor ligands are therefore an unmet medical need [1]. Rational lead discovery approaches are not possible due to the lack of a high-resolution structure of this pentameric transmembrane receptor [2].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
